碳增强的聚醚醚酮作为髋臼假体材料的实验研究

目的:评价碳纤维增强的聚醚醚酮(CFPEEK)作为髋臼假体材料的生物相容性和耐磨损性。方法:(1)采用国产材料和工艺研制出碳纤CFPEEK复合材料,在模拟体液环境下对其本身以及与不同磨擦偶的耐磨损性能进行测试,并与传统髋臼假体材料超高分子聚乙烯(UHMWPE)作比较。(2)体外研究CFPEEK磨屑对巨噬细胞ANA-1释放白细胞介素1(IL-1_β)和肿瘤坏死因子α(TNF-α)的影响,并与传统的人工关节材料比较,以确定各材料间生物学反应的差异。结果:(1)CFPEEK的体积磨损率只为UHMWPE的1/2,耐磨损性能明显优于UHMWPE(Alpha=0.01水平)。CFPEEK与钴铬钼合金(CoCrMo)对磨将产生最少的磨屑(Alpha=0.01水平)。CFPEEK与CoCrMo对磨时的摩擦系数最低。(2)各实验组IL_(-1β)和TNF-α的释放都有增高,实验结果总体差异有显著性意义(P=0.0001),UHMWPE组明显高于CFPEEK组(Alpha=0.01水平)。结论:CFPEEK材料具耐磨损、生物相容性好的特点,是一种未来髓臼假体的理想材料。     

二氢青蒿素对胰腺癌生长的抑制作用

Objective To investigate the anti-tumor activity of dihydroartemisinin in pancreatic cancer in vitro and in vivo. Methods For cultured cells,cell growth was determined by the MTT assay and apoptosis was evaluated by flow cytometry analysis stained with Annexin V-FITG/PI. The protein expression in BxPC-3 cells was analyzed by Western blot assay. BxPC-3 cells were injected subcutaneously into nude mice to establish pancreatic xenograft tumors and the tumor volume was monitored after exposure to dihydroartemisinin. Ki-67 staining and TUNEL assay were used to assess tumor cell proliferation and apoptosis in tumor tissue. Results After treatment by dihydroartemisinin in vitro, the proliferative inhibition rates of pancreatic cancer cells BxPC-3 and AsPC-1 reached up to (76.2 ± 3.5) % and (79.5 ± 2.9) %, and the apoptosis rates were up to (55.5 ± 3.2)% and (40.0 ± 3.5)%, the differences were significantly (P ＜ 0.01) compared with control [(2.0 ± 1.3) % and (0.9 ± 0.4) %]. Dihydroartemisinin inhibited the growth of pancreatic xenograft tumors in nude mice. The proliferation index and apoptusis index were (49.1 ± 3.9)% and (50.2 ± 4.4)% respectively in dihydroarternisinin 50 mg/kg treatment group, compared to those of (72.1 ± 3.3) % and (9.4 ± 2.9) % in control, the differences were significantly (P ＜0.01). Western blot assay indicated that dihydroartemisinin up-regulates expression of proliferation-associated protein p21WAF1 and down-regulates expression of PCNA, increases expression of apoptosis-associated protein Bax and decreases expression of Bcl-2 and activates caspase-9 in BxPC-3 cells. Conclusions Dihydroartemisinin exerts anti-tumor activity in pancreatic cancer both in vitro and in vivo by proliferation inhibition and apoptusis induction. Dihydroartemisinin can be used as a potential anti-tumor drug in pancreatic cancer.     

踝关节骨折的手术治疗

目的 探讨手术治疗踝关节骨折的疗效.方法 回顾性分析2000年1月至2008年4月手术治疗且有完整随访资料的92例踝父节骨折患者的疗效.评价指标包括美国足踝机会踝与后足功能评分(AOFAS评分)、骨折部位的疼痛评估(VAS评分)、患者满意度、踝关节活动度.并对踝关节健侧与患侧的关节活动度差异,以及不同AO分型之间、骨折累及不同部位(单踝、双踝、三踝骨折)之间、不同随访时限之间这二种情况下的踝关节屈伸活动度及AOFAS评分的差异进行统计学分析.结果 平均随访55个月,所有患者骨折均愈合;AOFAS评分平均为93.6分,优良率100%;VAS评分平均为0.17分,患者满意度评分平均为9.62分.健、患侧踝关节活动度差异有统计学意义(P<0.05),不同AO分型之间、骨折累及小同部位之问、不同随访时限之问的踝关节屈伸活动度和AOFAS评分差异无统计学意义(P>0.05).结论 手术治疗踝关节骨折可取得满意的临床疗效.     

FK506-壳聚糖膜与体外培养雪旺细胞生物相容性的研究

目的 探讨FK506-壳聚糖膜片与培养的雪旺细胞生物相容性.方法 将生长状况和纯度较好的第3代雪旺细胞,分别传代接种于含有FK506-壳聚糖膜片、单纯壳聚糖膜片的培养皿中培养,以盖玻片作为对照组.计算3组雪旺细胞倍增时间、雪旺细胞纯度;用MTT法比较不同膜片上雪旺细胞的生长活力,绘制生长曲线;S-100免疫荧光染色.结果 雪旺细胞倍增时间对照组为5.9 d,单纯壳聚糖膜片及FK506-壳聚糖膜片组均为4.0 d;雪旺细胞纯度分别为80%、89%,93%;雪旺细胞增殖情况以FK506-壳聚糖组最佳,单纯壳聚糖组次之,对照组最差;各组雪旺细胞均呈S-100阳性,FK506-壳聚糖组与单纯壳聚糖组雪旺细胞排列呈典型的漩涡状或栅栏状.结论 FK506-壳聚糖膜片具有更显著的组织相容性与生物功能性,并保持了雪旺细胞的生物学特性.     

谷氨酰胺和生长激素对门静脉高压症患者术后营养、免疫和炎症反应的影响

Objective This study was conducted to evaluate the effects of postoperative glutamine and growth hormone on the nutritional status,immune function,and inflammatory responses of patients undergo-ing portal hypertension surgery.Methods This study was designed as a prospective,randomized and con-trolled clinical trial.Forty-two patients undergoing portal hypertension surgery were randomly divided into 2 groups:experimental group (receiving an immune enhancing parenteral nutrition by adding glutamine and re-combinant human growth hormone,n = 22),and control group (receiving an isocaloric and isonitrogenons standard parenteral nutrition,n = 20).Parenteral nutrition providing 125 kJ · kg-1·d-1 was initiated 3 days after surgery in both groups and last for 7 days.Blood samples were obtained on day 0th,3rd,and 10th.Host nutritional status was evaluated by measuring levels of prealbumin and transferrin,immunity was evalu-ated by measuring levels of CD4,CD8,CD4/CD8,IgG,IgM and IgA,and the inflanunatory responses was determined by assessing IL-2,TNF-α and C-reactive protein (CRP) levels.Results Ten days after opera-tion,among patients receiving an immune enhancing parenteral nutrition,the serum prealbumin was (193.84±39.78)mg/L,transferrin was (2.07±0.51)mg/L,CD4 was (33.7±5.5)%,CD4/CD8 was (1.17±0.32),IgG was (13.94±1.09)g/L and IL-2 was (368.12±59.25) pg/mL.They were signifi-cantly higher than those of the control group (P < 0.05).The TNF-α concentrations was (321.12±81.42)pg/mL and CRP was (32.2±15.2)mg/mL which were significantly lower than those of the control group (P < 0.05).Conclusion Postoperative administration of immune enhancing parentearl nutrition in patients undergoing portal hypertension surgery can improve nutritional status and immune function,and modulate inflammatory response is also better than standard one.     

中央型颈脊髓损伤保守与手术治疗的对比研究

目的对比研究手术与非手术治疗中央型颈脊髓损伤的临床疗效。方法中央型颈脊髓损伤患者120例,手术治疗72例,其中前路手术28例,后路手术44例;非手术治疗48例。详细记录患者ASIA运动功能评分(AMS),对治疗前及治疗后6个月、2年时的AMS评分进行比较。结果96例获随访,时间6个月~5年,21例失访,3例死亡。两组治疗后6个月、2年时AMS评分之间差异有显著性(P<0.05)。治疗后6个月内非手术组6例出现并发症(6/48,12.5%),手术组4例出现并发症(4/72,5.6%),两组之间差异无显著性(P>0.05)。结论手术治疗中央型颈脊髓损伤疗效可靠。早期手术能够解除脊髓压迫,稳定颈椎,促进脊髓功能恢复。     

精子冷冻环无保护剂玻璃化冷冻方法的初步研究

目的探讨精子冷冻环无保护剂玻璃化冷冻方法的可行性。方法正常精液标本上游处理后,进行常规冷冻和冷冻环无保护剂的玻璃化冷冻,复苏后分别从活力参数及电镜下超微结构等指标比较两种冷冻方法的效果。结果两种方法冷冻后精子存活率、活动率之间差异无显著性(48%∶48%;44.5%∶43.5%,P>0.05),但均较未冷冻的89%和88.5%明显下降(P<0.001)。超微结构亦较未冷冻时发生了一定的改变,但核结构基本保持完整。结论精子冷冻环无保护剂的玻璃化冷冻是一种简单、方便而行之有效的冷冻方法。     

羟考酮对腹腔镜胆囊切除术患者拔管期应激反应、术后疼痛的影响分析

目的分析羟考酮对腹腔镜胆囊切除术患者拔管期应激反应、术后疼痛的影响分析。方法收集行腹腔镜胆囊切除术治疗的患者120例,ASA分级为Ⅰ~Ⅱ级,根据随机数字表法分为4组(每组30例),A、B、C组分别于术前15min静脉注射0.1mg/kg、0.15mg/kg、0.2mg/kg的羟考酮,D组静脉注射相同剂量的生理盐水。比较4组患者术后VAS评分、Ramsay镇静评分和炎性因子水平,并比较4组患者静脉注射羟考酮即刻(T1)、拔管即刻(T2)及拔管后5(T3)、10min(T4)的平均动脉压(MAP)、心率(HR)、血清肾上腺素(E)、皮质醇(Cor)水平。结果 C组拔管时间、苏醒时间明显高于A组、B组和D组(P0.05);B组、C组T2、T3时刻MAP、HR均明显低于A组和D组(P0.05);B组、C组T2、T3、T4时刻血清E、Cor水平明显低于A组和D组(P0.05);B组、C组术后1、2、6h的VAS评分明显低于A组和D组(P0.05);C组术后1、2、6h的Ramsay评分明显高于A组、B组和D组(P0.05);D组术后6、12h血IL-6水平均明显高于A组、B组和C组,术后6、12、24h血IL-10水平均明显高于A组、B组和C组(P0.05);B组、C组术后6、12h血IL-6水平均明显低于A组,IL-10水平均明显高于A组(P0.05);C组恶心呕吐、嗜睡、头晕发生率明显高于A组、B组和D组(P0.05)。结论腹腔镜胆囊切除术患者术前15min静脉注射0.15mg/kg的羟考酮,可更加有效减轻拔管期应激反应,改善了术后疼痛和炎症反应,且未增加不良反应的发生和拔管时间、苏醒时间,值得临床重视。     

大肠癌黏蛋白1和β-连环素联合表达的临床意义

目的 探讨大肠癌黏蛋白1(MUC1)与β-连环素(β-catenin)表达的临床意义.方法 应用免疫组织化学法检测90例大肠癌标本MUC1与β-catenin表达,分析两种分子标志的分布类型与大肠癌临床病理的关系;进一步检验MUC1表达与β-catenin分布的关系,评价联合表达对临床预后的判断价值.结果 54.44%出现MUC1极性分布的丧失,与肿瘤浸润深度相关(P＜0.05),而58.89%出现β-catenin核转移,与大肠癌TNM分期有关(P＜0.05).MUC1与核β-catenin的联合表达与大肠癌淋巴结转移和TNM分期相关(P＜0.01);联合表达阳性者生存率显著低于阴性者(P＜0.05).结论 MUC1极性分布的丧失与β-catenin核转移相关,两者联合表达的阳性提示较差的临床预后.

Abstract：

Objective To investigate the clinical significance of combined expression of mucin 1(MUC1) and β-catenin in colorectal cancer. Methods Ninety colorectal cancer specimens were subjected to immunohistochemistry for detection of MUC1 and β-catenin. The relationships of expression patterns of these two biomarkers and clinicopathological parameters and survival were analyzed. Results Loss of polarity distribution of MUC1 was detected in 54. 44% cases and was related to depth of invasion ( P ＜0.05), and nuclear translocation of β-catenin was found in 58. 89% cases and correlated with TNM stage (P ＜0.05). The combined expression of MUC1 and nucrear β-catenin was related to lymph node metastasis and TNM stage (P ＜ 0.01 ) and also, a significantly lower survival rate (P ＜0.05 ). Conclusion Combined expression of MUC1 and nuclear β-catenin indicated a worse prognosis in colorectal cancer.     

化疗对CD133+结肠癌细胞的作用效果

目的 观察化疗前后结肠癌细胞株HT29、SW620中CD133+结肠癌细胞的数量变化,探讨化疗对CD133+结肠癌细胞的作用效果.方法 取对数生长的结肠癌细胞株HT29、SW620,采用80 mg/L 5-氟尿嘧啶(5-Fu)和25 mg/L奥沙利铂(Oxaliplatin)分别作用8 h,并设对照组,利用CD133抗体进行标记后再用流式细胞仪进行检测,观察化疗前后CD133+细胞的比例.结果 流式细胞仪检测结肠癌细胞株HT29,80 mg/L 5-Fu处理8 h组中CD133+肿瘤细胞为45.00%,与未处理组(32.80%)比较结果差异有统计学意义(P＜0.01);25 mg/L奥沙利铂处理8 h组中CD133+肿瘤细胞为55.30%,与未处理组和80 mg/L 5-Fu处理8 h组比较结果差异有统计学意义(P＜0.01).流式细胞仪检测结肠癌细胞株SW620,80 mg/L 5-Fu处理8 h组中CD133+肿瘤细胞为47.10%,与未处理组(33.90%)比较结果差异有统计学意义(P＜0.01);25 mg/L奥沙利铂处理8 h组中CD133+肿瘤细胞为56.50%,与未处理组和80 mg/L 5-Fu处理8 h组比较结果差异有统计学意义(P＜0.01).结论 CD133+结肠癌细胞能明显抵抗化疗.

Abstract：

Objective To observe the changes of quantity of CD133 + cells in HT29 and SW620 cell lines before and after chemotherapy, and detect the effect of chemotherapy on CD133 + cells. Methods HT29 and SW620 cells in logarithmic growth phase were separately treated with 80 mg/L 5-fluorouracil(5-Fu) and 25 mg/L oxaliplatin for 8 h, and analyzed by flow cytometry after being marked by CD133 antibody. The proportion of CD133 + cells before and after chemotherapy was measured. Results For HT29 cells, the proportion of CD133 + cancer cells in the group treated with 80 mg/L 5-Fu for 8 h was 45.00% with the difference being remarkable ( P ＜ 0. 01 ) compared to the non-treatment group ( 32. 80% ). The proportion of CD133 + cancer cells in the group treated with 25 mg/L oxaliplatin for 8 h was 55.30% with the difference being remarkable ( P ＜ 0. 01 ) compared with both the non-treatment group and the group treated with 80 mg/L 5-Fu for 8 h. For SW620 cells, the proportion of CD133 + cancer cells in the group treated with 80 mg/L 5-Fu for 8 h was 47. 10% with the difference being remarkable ( P ＜0. 01 ) compared with the non-treatment group (33.90%). The proportion of CD133 + cancer cells in the group treated with 25 mg/L oxaliplatin for 8 h was 56. 50% with the difference being remarkable ( P ＜ 0. 01 ) compared with both the non-treatment group and the group treated with 80 mg/L 5-Fu for 8 h. Conclusion CD133 positive colon cancer cells have anti-chemotherapy activity obviously.